{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:13:17Z","timestamp":1772255597061,"version":"3.50.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) and experimental autoimmune myasthenia gravis (EAMG) are caused by Ab-mediated autoimmune responses to muscle nicotinic acetylcholine receptors (AChRs) that impair neuromuscular transmission, thereby causing muscle weakness. Previously, we discovered that i.p. injection of a therapeutic vaccine consisting of bacterially expressed cytoplasmic domains of human AChR subunits reduced the development of chronic EAMG in rats. In this article, we show that immunization with the therapeutic vaccine in adjuvants does not induce EAMG and, thus, is safe. The potency and efficacy of the therapeutic vaccine were greatly increased by s.c. administration of repeated low doses in IFA. Onset of chronic EAMG could be prevented. Established chronic EAMG could be rapidly reversed, modeling therapy of chronic MG. Therapy reduced pathological Abs assayed by immune precipitation of a main immunogenic region chimera. Successfully treated rats exhibited long-term resistance to reinduction of EAMG, suggesting a lasting cure of MG. A long-term effect of therapy was to change the isotype of the pathogenic Ab response from IgG2b, which fixes complement, to IgG1, which does not. Prevention and reversal of chronic EAMG was not caused by the isotype switch, but the isotype switch may contribute to resistance to reinduction of EAMG. Immunization with AChR cytoplasmic domains in adjuvant is promising as a safe, Ag-specific, potent, effective, rapidly acting, and long-lasting therapeutic approach to MG.<\/jats:p>","DOI":"10.4049\/jimmunol.1401392","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T03:44:17Z","timestamp":1412653457000},"page":"5044-5055","source":"Crossref","is-referenced-by-count":22,"title":["Antigen-Specific Immunotherapeutic Vaccine for Experimental Autoimmune Myasthenia Gravis"],"prefix":"10.1093","volume":"193","author":[{"given":"Jie","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Neuroscience, University of Pennsylvania Medical School , Philadelphia, PA 19104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Lindstrom","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Pennsylvania Medical School , Philadelphia, PA 19104"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,11,15]]},"reference":[{"key":"2025030707461959100_r1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"2025030707461959100_r2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve"},{"key":"2025030707461959100_r3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin. Neurol."},{"key":"2025030707461959100_r4","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2025030707461959100_r5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom","year":"2000","journal-title":"Muscle Nerve"},{"key":"2025030707461959100_r6","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J. Neurosci."},{"key":"2025030707461959100_r7","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.141.6.1365","article-title":"Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs","volume":"141","author":"Lennon","year":"1975","journal-title":"J. Exp. Med."},{"key":"2025030707461959100_r8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1084\/jem.144.3.726","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J. Exp. Med."},{"key":"2025030707461959100_r9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08916934.2011.622015","article-title":"Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors","volume":"45","author":"Luo","year":"2012","journal-title":"Autoimmunity"},{"key":"2025030707461959100_r10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707461959100_r11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","article-title":"Immunotherapy in autoimmune neuromuscular disorders","volume":"2","author":"Gold","year":"2003","journal-title":"Lancet Neurol."},{"key":"2025030707461959100_r12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2625","article-title":"Optimization of current and future therapy for autoimmune diseases","volume":"18","author":"Steinman","year":"2012","journal-title":"Nat. Med."},{"key":"2025030707461959100_r13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ana.22025","article-title":"Zero tolerance (to acetylcholine receptor) and ways to overcome it","volume":"67","author":"Wekerle","year":"2010","journal-title":"Ann. Neurol."},{"key":"2025030707461959100_r14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/clin.1997.4432","article-title":"Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases","volume":"85","author":"Xiao","year":"1997","journal-title":"Clin. Immunol. Immunopathol."},{"key":"2025030707461959100_r15","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.146.7.2245","article-title":"Recombinant human acetylcholine receptor \u03b1-subunit induces chronic experimental autoimmune myasthenia gravis","volume":"146","author":"Lennon","year":"1991","journal-title":"J. Immunol."},{"key":"2025030707461959100_r16","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.4049\/jimmunol.165.7.3599","article-title":"Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis","volume":"165","author":"Im","year":"2000","journal-title":"J. Immunol."},{"key":"2025030707461959100_r17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molimm.2008.08.264","article-title":"Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor","volume":"46","author":"Yi","year":"2008","journal-title":"Mol. Immunol."},{"key":"2025030707461959100_r18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.autrev.2013.03.006","article-title":"Novel future therapeutic options in myasthenia gravis","volume":"12","author":"Dalakas","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"2025030707461959100_r19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.21901","article-title":"Specific immunotherapy of experimental myasthenia gravis by a novel mechanism","volume":"67","author":"Luo","year":"2010","journal-title":"Ann. Neurol."},{"key":"2025030707461959100_r20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1749-6632.1976.tb47691.x","article-title":"Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects","volume":"274","author":"Lindstrom","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707461959100_r21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1749-6632.1976.tb47693.x","article-title":"Experimental autoimmune myasthenia gravis: cellular and humoral immune responses","volume":"274","author":"Lennon","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707461959100_r22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-4899-1775-1_10","article-title":"Neuronal nicotinic acetylcholine receptors","volume":"4","author":"Lindstrom","year":"1996","journal-title":"Ion Channels"},{"key":"2025030707461959100_r23","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/eji.1830230816","article-title":"Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies","volume":"23","author":"Mamalaki","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"2025030707461959100_r24","first-page":"171","article-title":"Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system","volume":"43","author":"Medgyesi","year":"1981","journal-title":"Immunology"},{"key":"2025030707461959100_r25","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J. Immunol."},{"key":"2025030707461959100_r26","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.1002942","article-title":"Foxp3+ regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells","volume":"186","author":"Jang","year":"2011","journal-title":"J. Immunol."},{"key":"2025030707461959100_r27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/ni1440","article-title":"Fc\u03b3RIIb controls bone marrow plasma cell persistence and apoptosis","volume":"8","author":"Xiang","year":"2007","journal-title":"Nat. Immunol."},{"key":"2025030707461959100_r28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707461959100_r29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1084\/jem.125.6.1119","article-title":"The effect of passively administered antibody on antibody synthesis","volume":"125","author":"Dixon","year":"1967","journal-title":"J. Exp. Med."},{"key":"2025030707461959100_r30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MOH.0b013e32833199ed","article-title":"Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?","volume":"16","author":"Brinc","year":"2009","journal-title":"Curr. Opin. Hematol."},{"key":"2025030707461959100_r31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.18.1.709","article-title":"Regulation of antibody responses via antibodies, complement, and Fc receptors","volume":"18","author":"Heyman","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"2025030707461959100_r32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jtbi.2006.01.019","article-title":"Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice","volume":"241","author":"Na","year":"2006","journal-title":"J. Theor. Biol."},{"key":"2025030707461959100_r33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with \u03b2-amyloid","volume":"15","author":"Cribbs","year":"2003","journal-title":"Int. Immunol."},{"key":"2025030707461959100_r34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"2025030707461959100_r35","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin. Exp. Immunol."},{"key":"2025030707461959100_r36","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"2025030707461959100_r37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J. Autoimmun."},{"key":"2025030707461959100_r38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"2025030707461959100_r39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"2025030707461959100_r40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2004.04.010","article-title":"Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment","volume":"152","author":"Maiti","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"2025030707461959100_r41","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1471-4906(02)02288-3","article-title":"Pathogen-specific regulatory T cells provoke a shift in the Th1\/Th2 paradigm in immunity to infectious diseases","volume":"23","author":"McGuirk","year":"2002","journal-title":"Trends Immunol."},{"key":"2025030707461959100_r42","first-page":"143","article-title":"Oral tolerance: therapeutic implications for autoimmune diseases","volume":"13","author":"Faria","year":"2006","journal-title":"Clin. Dev. Immunol."},{"key":"2025030707461959100_r43","doi-asserted-by":"crossref","first-page":"621693","DOI":"10.1155\/2013\/621693","article-title":"Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes","volume":"2013","author":"Cousens","year":"2013","journal-title":"J. Diabetes Res."},{"key":"2025030707461959100_r44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707461959100_r45","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J. Neurosci."},{"key":"2025030707461959100_r46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1152\/physrev.00015.2011","article-title":"End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease","volume":"92","author":"Sine","year":"2012","journal-title":"Physiol. Rev."},{"key":"2025030707461959100_r47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/10\/5044\/61496753\/1401392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/10\/5044\/61496753\/1401392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T03:18:02Z","timestamp":1741317482000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/193\/10\/5044\/7960626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,11,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1401392","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.719991843.793500723","asserted-by":"object"}]},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,11]]},"published":{"date-parts":[[2014,11]]}}}